Press Releases
January 22, 2015
Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy
"Zelig's award-winning research has been at the center of CAR T cell programs currently advancing in clinical studies. We are pleased to have an expanded agreement with Zelig and the
Professor Eshhar stated, "I have dedicated my career to the advancement of this transformative area of medicine, and I am excited about the opportunities before us."
Professor Eshhar continued, "Originally, my research had addressed the question of whether T cells can be programmed to effectively recognize and eliminate cancerous cells and to solve the central problem of how and why cancer cells escape the immune system. Now, we believe that we can further enhance this platform technology to develop a whole new generation of CAR T cell products for many tumor types. I look forward to the progress of this program." Professor Eshhar recently was named one of the recipients of the prestigious Massry Prize - along with Kite collaborator
About
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability of our collaborator to develop and advance CAR T cell therapy. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the
CONTACT: Kite Contacts:Claudine Prowse SVP, Corporate Communications and Investor Relations cprowse@kitepharma.com For Media:Justin Jackson Burns McClellan (212) 213-0006 jjackson@burnsmc.com
News Provided by Acquire Media